The nanoparticle is made of a biodegradable polymer that is loaded with two prodrugs that target cancer cells’ mitochondrial DNA, according to a May 6 article on the university’s website. One is a modified form of common chemotherapy drug cisplatin. The second is a drug researchers developed in the lab known as Mito-DCA.
In preclinical trials, the drug-loaded nanoparticle shrunk both breast tumors and breast cancer cells in the brain. The research was published May 6 in Proceedings of the National Academy of Sciences.
Researchers said they are still working to understand how these nanoparticles cross the blood-brain barrier and that more preclinical research is needed.
Learn more here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
